venetoclax (Rx)

Brand and Other Names:Venclexta
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 10mg
  • 50mg
  • 100mg

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Indicated for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least 1 prior therapy

Monotherapy

  • 20 mg PO qDay for 7 days initially, followed by a weekly ramp-up dosing schedule to the recommended daily dose of 400 mg
  • Dose ramp-up phase
    • Administer dose according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg
    • Week 1: 20 mg PO qDay
    • Week 2: 50 mg PO qDay
    • Week 3: 100 mg PO qDay
    • Week 4: 200 mg PO qDay
    • Week 5 and beyond: 400 mg PO qDay
    • Continue daily dose until disease progression or unacceptable toxicity
    • See Dosing Considerations and Dosage Modifications for tumor lysis syndrome (TLS) prophylaxis regimens

Combination with rituximab

  • In combination with rituximab, administer rituximab after the 5-week ramp-up schedule with venetoclax
  • Administer rituximab 375 mg/m² IV for Cycle 1 on Day 1, followed by 500 mg/m² IV on Day 1 for Cycles 2-6
  • Continue venetoclax 400 mg PO qDay for 24 months from Cycle 1 Day 1 of rituximab

Dosage Modifications

For patients who have had a dosing interruption >1 week during the first 5 weeks of ramp-up phase or >2 weeks after completing the ramp-up phase, reassess for risk of tumor lysis syndrome (TLS) to determine if reinitiation with a reduced dose is necessary (eg, all or some levels of the dose ramp-up schedule)

Consider discontinuing treatment for patients who require dose reductions to <100 mg for >2 weeks

Dose reduction schedule

  • Dose at interruption is 400 mg: Restart at 300 mg
  • Dose at interruption is 300 mg: Restart at 200 mg
  • Dose at interruption is 200 mg: Restart at 100 mg
  • Dose at interruption is 100 mg: Restart at 50 mg
  • Dose at interruption is 50 mg: Restart at 20 mg
  • Dose at interruption is 20 mg: Restart at 10 mg
  • During the ramp-up phase, continue the reduced dose for 1 week before increasing the dose

Tumor lysis syndrome

  • Modify for any occurrence of blood chemistry changes or symptoms suggestive of TLS
  • Withhold the next day’s dose; if resolved within 24-48 hr of last dose, resume at the same dose
  • For any blood chemistry changes requiring >48 hr to resolve, resume at a reduced dose
  • For any events of clinical TLS, resume at a reduced dose following resolution

Nonhematologic toxicities (Grade 3 or 4)

  • First occurrence: Interrupt dose; once toxicity resolves to Grade 1 or baseline level, resume at the same dose; no dose modification is required
  • Second and subsequent occurrences: Interrupt dose; follow dose reduction guidelines when resuming treatment after resolution; a larger dose reduction may occur at the physician’s discretion

Hematologic toxicities

  • Grade 3 or 4 neutropenia with infection or fever, or Grade 4 hematologic toxicities (except lymphopenia)
  • First occurrence: Interrupt dose; reduce the infection risks with neutropenia by administering G-CSF with venetoclax if clinically indicated; once toxicity resolves to Grade 1 or baseline level, resume at the same dose
  • Second and subsequent occurrences: Interrupt dose; consider using G-CSF as clinically indicated; follow dose reduction listed above when resuming after resolution; a larger dose reduction may occur at the discretion of the physician

Coadministration with CYP3A and/or P-gp inhibitors

  • Strong CYP3A inhibitor
    • Contraindicated during initiation and ramp-up phase
    • At steady daily dose (ie, after ramp-up phase): Avoid strong inhibitor or reduce venetoclax dose by at least 75%
  • Moderate CYP3A inhibitor or P-gp inhibitor
    • Avoid strong inhibitor or reduce venetoclax dose by at least 50%
  • Resume the venetoclax dose used prior to initiating the CYP3A inhibitor or P-gp inhibitor 2-3 days after discontinuation of the inhibitor

Dosing Considerations

Patients without 17p deletion at diagnosis should be retested at relapse because acquisition of 17p deletion can occur

TLS risk

  • Assess patient-specific factors for level of risk of TLS and provide prophylactic hydration and antihyperuricemics to patients prior to first dose to reduce risk of TLS
  • Venetoclax can cause rapid reduction in tumor and thus poses a risk for TLS in the initial 5­week ramp-up phase
  • Changes in blood chemistries consistent with TLS that require prompt management can occur as early as 6-8 hr after the first dose and at each dose increase
  • The risk of TLS is a continuum based on multiple factors, including tumor burden and comorbidities
  • Perform tumor burden assessments, including radiographic evaluation (eg, CT scan); assess blood chemistry (potassium, uric acid, phosphorus, calcium, and creatinine) in all patients and correct preexisting abnormalities prior to initiating
  • Reduced renal function (CrCl <80 mL/min) further increases the risk
  • Risk may decrease as tumor burden decreases

TSL prophylaxis

  • Low tumor burden
    • All lymph nodes (LNs) <5 cm AND absolute lymphocyte count (ALC) <25 x10^9/L
    • Give oral hydration of 1.5-2 L and allopurinol 2-3 days before initiating venetoclax
    • Outpatient: Monitor blood chemistry predose, at 6-8 hr, and 24 hr after first dose and predose for subsequent ramp-up doses
  • Medium tumor burden
    • Any LN 5 cm to <10 cm OR ALC ≥25 x10^9/L
    • Give oral hydration of 1.5-2 L (also consider additional IV hydration) and allopurinol or xanthine oxidase inhibitor 2-3 days before initiating venetoclax
    • Outpatient: Monitor blood chemistry predose, at 6-8 hr, and 24 hr after first dose and predose for subsequent ramp-up doses; consider hospitalization for patients with CrCl <80 mL/min at first dose of 20 mg and 50 mg
  • High tumor burden
    • Any LN ≥10 cm OR, ALC ≥25 x10^9/L AND any LN ≥5 cm
    • Hydration: Oral (1.5-2 L) and IV (150-200 mL/hr as tolerated)
    • Give allopurinol 2-3 days before initiating venetoclax; consider rasburicase if baseline uric acid is elevated
    • Inpatient: Monitor blood chemistry at first dose of 20 mg and 50 mg; predose, 4, 8, 12, and 24 hr
    • Outpatient: Monitor blood chemistry at subsequent ramp-up doses; predose, at 6-8 hr, and 24 hr after dose

Orphan Designations

Acute myeloid leukemia

Multiple myeloma

Mantle cell lymphoma

Sponsor

  • AbbVie Inc; 1 Waukegan Road, Dept PA77, Bldg. AP30; North Chicago, Illinois 60044

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and venetoclax

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            All grades of severity listed unless otherwise indicated

            >10% (Combination with rituximab)

            Leukopenia (89%)

            Lymphopenia (87%)

            Neutropenia (65-86%)

            Neutropenia, Grade 3 or 4 (62-64%)

            Hypocalcemia (62%)

            Hypophosphatemia (57%)

            Lymphopenia, Grade 3 or 4 (56%)

            Leukopenia, Grade 3 or 4 (46%)

            Diarrhea (43%)

            Increased AST/SGOT (46%)

            Diarrhea (40%)

            Upper respiratory tract infection (39%)

            Hyperuricemia (36%)

            Increased alkaline phosphatase (35%)

            Hyperbilirubinemia (33%)

            Hyponatremia (30%)

            Hypokalemia (29%)

            Hyperkalemia (24%)

            Hypernatremia (24%)

            Nausea (21%)

            Musculoskeletal pain (19%)

            Lower respiratory tract infection (18%)

            Anemia (16%)

            Thrombocytopenia (15%)

            Constipation (14%)

            Hypophosphatemia, Grade 3 or 4 (14%)

            Abdominal pain (13%)

            Rash (13%)

            Headache (11%)

            Insomnia (11%)

            >10% (Monotherapy)

            Neutropenia (50%)

            Neutropenia, Grade 3 or 4 (45%)

            Nausea (42%)

            Upper respiratory tract infection (36%)

            Anemia (33%)

            Fatigue (32%)

            Thrombocytopenia (29%)

            Edema (22%)

            Thrombocytopenia, Grade 3 or 4 (20%)

            Anemia, Grade 3 or 4 (18%)

            Abdominal pain (18%)

            Pyrexia (18%)

            Vomiting (16%)

            Constipation (16%)

            Mucositis (13%)

            Lymphopenia (11%)

            1-10% (Combination with rituximab)

            Mucositis (10%)

            Pneumonia (10%)

            Vomiting (8%)

            Lymphopenia, Grade 3 or 4 (7%)

            Hyponatremia, Grade 3 or 4 (6%)

            Hypokalemia, Grade 3 or 4 (6%)

            Hypocalcemia, Grade 3 or 4 (5%)

            Febrile neutropenia (4%)

            Hyperbilirubinemia, Grade 3 or 4 (4%)

            Diarrhea, Grade 3 or 4 (3%)

            Tumor lysis syndrome, Grade 3 or 4 (3%)

            Hyperkalemia, Grade 3 or 4 (3%)

            Upper respiratory tract infection, Grade 3 or 4 (2%)

            Lower respiratory tract infection, Grade 3 or 4 (2%)

            Increased AST/SGOT (2%)

            Hypernatremia, Grade 3 or 4 (1%)

            Musculoskeletal pain, Grade 3 or 4 (1%)

            Increased alkaline phosphatase, Grade 3 or 4 (1%)

            1-10% (Monotherapy)

            Febrile neutropenia (6%)

            Fatigue, Grade 3 or 4 (4%)

            Abdominal pain, Grade 3 or 4 (3%)

            Diarrhea, Grade 3 or 4 (3%)

            Edema, Grade 3 or 4 (2%)

            Nausea, Grade 3 or 4 (1%)

            Vomiting, Grade 3 or 4 (1%)

            Upper respiratory tract infection, Grade 3 or 4 (1%)

            <1%

            Monotherapy

            • Constipation, Grade 3 or 4
            • Mucositis, Grade 3 or 4
            • Pyrexia, Grade 3 or 4
            Previous
            Next:

            Warnings

            Contraindications

            Strong CYP3A inhibitors at initiation and during ramp-up phase

            Cautions

            Tumor lysis syndrome, including fatal events and renal failure requiring dialysis, has occurred in previously treated CLL patients with high tumor burden when treated with venetoclax (see Dosing Considerations and Dosage Modifications)

            Neutropenia frequently reported; monitor complete blood counts throughout the treatment period (see Dosage Modifications and Adverse Effects)

            Do not administer live attenuated vaccines prior to, during, or after treatment until B-cell recovery occurs; safety and efficacy of immunization with live attenuated vaccines during or following therapy have not been studied; advise patients that vaccinations may be less effective

            Based on its mechanism of action and findings in animals, may cause embryofetal harm when administered to a pregnant woman (see Pregnancy)

            Drug interaction overview

            • Also see, Dosage Modifications, Contraindications, and Drug Interaction Checker
            • Venetoclax in a CYP3A substrate
            • Coadministration with CYP3A inhibitors: Contraindicated during ramp-up phase; reduce dose of venetoclax while on steady daily dose
            • Coadministration with moderate CYP3A inhibitor and P-gp inhibitors: Reduce dose of venetoclax
            • If inhibitor discontinued, resume venetoclax dose used prior to initiating the CYP3A or P-gp inhibitor
            • Venetoclax effect on other drugs
              • Venetoclax has inhibition potential on P-gp substrates at therapeutic dose levels in the gut; therefore, coadministration of narrow therapeutic index P-gp substrates should be avoided
              • Administration of a single dose of venetoclax with warfarin resulted in an 18-28% increase in Cmax and AUC of R-warfarin and S-warfarin; monitor INR closely if coadministered
            Previous
            Next:

            Pregnancy

            Pregnancy

            There are no available human data on use in pregnant women; based on its mechanism of action and findings in animals, may cause embryofetal harm when administered to a pregnant woman

            Females of reproductive potential should undergo pregnancy testing before initiation

            Animal studies

            • In mice, venetoclax was fetotoxic at exposures 1.2 times the human clinical exposure based on AUC at the recommended human dose of 400 mg daily

            Fertility and contraception

            • Advise females of reproductive potential to use effective contraception during treatment and for at least 30 days after the last dose
            • Male fertility may be compromised by treatment

            Lactation

            Unknown if distributed in human breast milk; advise nursing women to discontinue breastfeeding during treatment

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Selective inhibitor of the B-cell lymphoma 2 (Bcl-2) regulator protein, an antiapoptotic protein

            Overexpression of Bcl-2 has been demonstrated in CLL cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutic agents

            Venetoclax helps restore the process of apoptosis by binding directly to the Bcl-2 protein, displacing proapoptotic proteins like BIM (a novel member of the Bcl-2 family), triggering mitochondrial outer membrane permeabilization, and activating caspases

            Absorption

            Peak plasma time: 5-8 hr

            Peak plasma concentration: 2.1 mcg/mL (400 mcg//day)

            AUC: 32.8 mcg·hr/mL (400 mcg//day)

            Distribution

            Protein bound: >99.9%

            Vd: 256-321 L

            Metabolism

            Metabolized by CYP3A4/5

            M27 was identified as a major metabolite in plasma with an inhibitory activity against Bcl-2 that is at least 58-fold lower than venetoclax in vitro

            Elimination

            Half-life: 26 hr

            Excretion: >99.9% in feces; <0.1% in urine

            Previous
            Next:

            Administration

            Oral Administration

            Administer 1 time a day with a meal and water at about the same time each day

            Swallow whole; do not chew, crush, or break the tablets

            Missed dose

            • If dose is missed within 8 hr of the time it is usually taken, take as soon as possible
            • If a patient misses a dose by >8 hr, skip dose and resume the usual dosing schedule the next day
            • If the patient vomits following dosing, do not take an extra dose; the next prescribed dose should be taken at the usual time

            Storage

            Tablets: Store at ≥86°F (30°C); keep tablets in the original package during the first 4 weeks of treatment; do not transfer the tablets to a different container

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.